These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8911877)

  • 21. Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration.
    Binkley PF; Nunziata E; Cody RJ
    Am Heart J; 1994 Dec; 128(6 Pt 1):1147-56. PubMed ID: 7985595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
    Moe GW; Rouleau JL; Charbonneau L; Proulx G; Arnold JM; Hall C; de Champlain J; Barr A; Sirois P; Packer M
    Am Heart J; 2000 Apr; 139(4):587-95. PubMed ID: 10740139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failure.
    Markus H; Cowley AJ
    Eur J Clin Pharmacol; 1991; 40(6):535-8. PubMed ID: 1884731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central and regional hemodynamic effects of flosequinan for congestive heart failure.
    Haas GJ; Binkley PF; Carpenter JA; Leier CV
    Am J Cardiol; 1989 Jun; 63(18):1354-9. PubMed ID: 2658526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of flosequinan in heart failure.
    Cowley AJ
    Am Heart J; 1991 Mar; 121(3 Pt 1):983-8. PubMed ID: 2000777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction.
    Schneeweiss A; Wynne RD; Marmor A
    Jpn Heart J; 1989 Sep; 30(5):627-34. PubMed ID: 2614925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placebo-controlled trial of flosequinan in moderate heart failure. The possible importance of aetiology and method of analysis in the interpretation of the results of heart failure trials.
    Cowley AJ; McEntegart DJ
    Int J Cardiol; 1993 Feb; 38(2):167-75. PubMed ID: 8454379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of the hemodynamic effects of the long-acting peripheral vasodilator flosequinan in patients with chronic heart failure].
    Abdurakhmanov US; Naumov VG; Shevliagin SA; Novikov SV; Mareev VIu; Belenkov IuN
    Kardiologiia; 1991 Nov; 31(11):49-51. PubMed ID: 1805065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure.
    Bartels GL; Remme WJ; Look MP; Kruijssen DA
    J Card Fail; 1995 Mar; 1(2):117-25. PubMed ID: 9420641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of low-dose flosequinan on left ventricular systolic and diastolic chamber performance.
    Starling MR
    Am Heart J; 1994 Jul; 128(1):124-33. PubMed ID: 8017265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of flosequinan in patients with heart failure of acute onset complicating acute myocardial infarction.
    Schneeweiss A; Wynne RD; Marmor A
    Int J Cardiol; 1989 Jul; 24(1):73-6. PubMed ID: 2668206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers.
    Duranteau J; Pussard E; Edouard A; Samii K; Berdeaux A; Giudicelli JF
    Br J Clin Pharmacol; 1992 Sep; 34(3):207-14. PubMed ID: 1389945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog.
    Greenberg S; Touhey B
    J Cardiovasc Pharmacol; 1990 Jun; 15(6):900-10. PubMed ID: 1694912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure.
    Burstein S; Semigran MJ; Dec GW; Boucher CA; Fifer MA
    J Am Coll Cardiol; 1992 Oct; 20(4):822-9. PubMed ID: 1527293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flosequinan induces hemodynamic improvement in heart failure complicating acute myocardial infarction.
    Schneeweiss A; Marmor A; Wynne RD
    Herz; 1988 Aug; 13(4):259-62. PubMed ID: 3169679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction.
    Schneeweiss A; Wynne RD; Marmor A
    Crit Care Med; 1989 Sep; 17(9):879-81. PubMed ID: 2766758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
    Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
    Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.
    Cohn JN; Ziesche S; Smith R; Anand I; Dunkman WB; Loeb H; Cintron G; Boden W; Baruch L; Rochin P; Loss L
    Circulation; 1997 Aug; 96(3):856-63. PubMed ID: 9264493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy.
    Dakak N; Makhoul N; Merdler A; Yechiely H; Kahana L; Halon DA; Schneeweiss A; Lewis BS
    Eur Heart J; 1993 Jun; 14(6):836-44. PubMed ID: 8325314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
    Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH
    Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.